<DOC>
	<DOCNO>NCT00641771</DOCNO>
	<brief_summary>To compare change fractional calcium absorption follow administration MK0217A relative matching placebo , postmenopausal woman osteoporosis</brief_summary>
	<brief_title>4-Week Study Assess Effect Alendronate Vitamin D3 Once Weekly Fractional Calcium Absorption Postmenopausal Osteoporotic Women ( 0217A-230 )</brief_title>
	<detailed_description>Placebo administer 4 week , single-blind run-in phase . Calcium , citrate-malate , administer throughout study individualize dose supplement patient 's daily dietary calcium intake total approximately 1200 mg. At end stabilization period , baseline calcium absorption determine patient randomize receive either MK0217A , match placebo weekly 4 week .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>The patient postmenopausal osteoporotic female The patient willing limit direct sunlight exposure course study The patient must ambulatory The patient serum 25hydroxyvitamin D =25 ng/mL The patient contraindicate bisphosphonate therapy The patient vitamin D deficiency Patient exclude weight 85 kg The patient history prior osteoporotic fracture The patient currently receive past treatment effect bone calcium metabolism The patient malabsorption syndrome The patient active thyroid disease The patient metabolic bone disease The patient myocardial infarction within 6 month screen visit The patient impair renal function The patient currently smoker last year</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>